August 2016 Analysis

Industry Trend Analysis - Generic Competition To Hurt AstraZeneca's 2016 Sales - AUG 2016

AstraZeneca's shareholders will keep a close eye on the company's late-stage R&D pipeline and newly launched USD1.1bn cost-cutting plan - assessing whether management's strategy has the strength to offset the revenue erosion caused by generic drugs. Nexium lost patent protection in the US in February 2015, and Crestor faces patent expiry in the US in 2016.